iCardio.ai
Overview
iCardio.ai offers FDA-cleared AI software designed to automate and enhance echocardiographic interpretation. The platform provides solutions for automated measurements (EchoMeasure™), disease detection such as aortic stenosis (CardioVision™), and objective image quality assessment. It aims to assist clinicians, enterprises, and institutions by integrating AI into existing PACS and hardware systems.
Key functionalities include automated ejection fraction prediction, real-time feature extraction and navigation for edge devices, and precise measurement of LVOT and aortic diameters. iCardio.ai also offers tools like EchoCheck for tracking image quality and completeness, Quantitative tools for automated linear and volumetric measurements, Qualitative tools for structural heart disease detection, and EchoGPT for image-to-text ultrasound descriptions. The company leverages a vast database of over 200 million individual images to develop its machine learning algorithms.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Automated echocardiographic measurements (EchoMeasureu2122)
- Automated detection of aortic stenosis (CardioVisionu2122)
- Objective image quality assessment
- Automated Ejection Fraction prediction
- Real-time feature extraction and navigation for edge devices
- LVOT and Aortic Diameters measurement
- Automated echocardiogram reports
- EchoCheck: Track image quality, echo completeness, and perspective classification
- Quantitative tools for automated linear and volumetric measurements
- EchoGPT: Image-to-text AI tool for ultrasound description
Use Cases
- Automating echo reports for enterprises and PACS integration
- Assisting clinicians in detecting structural heart disease like aortic stenosis
- Helping institutions assess and improve image quality for IAC accreditation
- Enhancing diagnostic accuracy and efficiency in echocardiography workflows
- Enabling increased access to cardiac diagnostics, especially with handheld ultrasound (POCUS)
- Providing data for clinical validation and custom AI model development
What Physicians Need to Know
iCardio.ai's tools are designed to automate and standardize echocardiogram interpretation, potentially reducing variability and improving efficiency. The automated measurements and disease detection capabilities, particularly for aortic stenosis, can serve as a valuable diagnostic aid. The image quality assessment feature can help maintain laboratory accreditation standards. While the AI provides preliminary reports and analysis, the final interpretation and clinical decision-making remain with the qualified healthcare practitioner. The real-time anatomical labeling can be particularly helpful for less experienced sonographers or in challenging imaging conditions.
iCardio.ai's solutions are delivered via API and through partnerships with PACS and ultrasound hardware vendors. They have established collaborations with UltraLinQ, deepc, HeartLab, SARC MedIQ, GE Healthcare, and Butterfly Network. The company is also collaborating with Abbott to integrate AI into their electrophysiology imaging product line, specifically for the EnSite X cardiac mapping system. iCardio.ai's technology can be integrated directly into PACS networks or hardware devices. Their EchoMeasure™ output is intended for consumption by third-party software and hardware vendors.
Details
| Category | Cardiology AI, Radiology & Imaging AI |
| Pricing | Unknown |
| Deployment | PACS, Hardware |
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Unknown |
| FDA Status | Cleared AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Cardiology, Radiology |
What the Web Says
iCardio.ai is a Los Angeles-based company that develops AI-powered solutions for echocardiography analysis, aiming to automate measurements, detect conditions like aortic stenosis, and generate reports. Their technology is designed to integrate into existing clinical workflows and hardware, with products like EchoMeasure and CardioVision having received FDA 510(k) clearance and Breakthrough Device Designation. The company emphasizes its large proprietary dataset of over 200 million ultrasound images as a key differentiator.
Overall: PositiveStrengths
- Automates echocardiography measurements and analysis, reducing manual effort and time for clinicians.
- Aims to improve accuracy and consistency in cardiac measurements by reducing human error and inter-observer variability.
- Integrates with existing cardiac imaging and reporting workflows, streamlining processes.
- Has FDA 510(k) clearances for EchoMeasure and CardioVision, and Breakthrough Device Designation for CardioVision.
- Leverages a large proprietary dataset of over 200 million ultrasound images for training its AI models.
- Potential to enhance diagnostic accuracy and efficiency, leading to earlier diagnosis and improved patient outcomes.
Limitations
- Physician confidence in their own interpretations can be a hurdle for AI adoption.
- Limited public reviews from physicians, healthcare IT, or tech reviewers directly on platforms like G2, Capterra, or Reddit.
- Adoption confidence in clinical AI is still developing gradually.
Based on reviews from: biotalent.com, saashub.com, medpath.com, producthunt.com, medstartr.ai, techbible.ai, tools.ai, medaxiom.com, nih.gov, icardio.ai, g2.com
Last updated: 2026-10-30
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate iCardio.ai
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for iCardio.ai.
AI in Action E492: Roman Sandler, Co-Founder and CTO at iCardio.ai
Alldus International
